AstraZeneca has become the latest big pharma company to devote new cash to its US manufacturing muscle this year as it ...

In the US, AstraZeneca has approximately 17,800 employees working across 17 R&D, manufacturing and commercial sites spanning ...

The jobs include roles in engineering and technical services and global supply chain functions. Read more at straitstimes.com ...

The boosted U.S. investment is said to be a response to Donald Trump’s election win, and leaves in doubt the pharmaceutical ...

The company said it aims to expand its U.S. presence by the end of 2026. The new spending will be for a research-and-development center in Cambridge, Mass.; manufacturing plants in Maryland and Texas, ...

AstraZeneca today announces $3.5 billion of capital investment ... the relationship that exists between a patient/site ...

Stay in the know with a recap of our top stories today. 1. AstraZeneca to open new $2b facility in Tuas by 2029, promises 800 ...

Alexion, and AstraZeneca Rare Disease have reported positive topline outcomes from the Phase III KOMET trial, assessing the ...

At about 23 hectares, the site will mark AstraZeneca’s largest to date in terms of initial build investment. It is targeted to be operationally ready by 2029 to produce antibody drug conjugates (ADCs) ...

AstraZeneca suffered a £14bn share price hit ... as well as the George House site in Leicester, to strengthen the company’s position for next year. The move comes after Asda has suffered ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that Åsa ...